SAB Biotherapeutics
SABS
37 hedge funds and large institutions have $4.45M invested in SAB Biotherapeutics in 2022 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 9 increasing their positions, 7 reducing their positions, and 3 closing their positions.
300% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 3
32% more funds holding
Funds holding: 28 → 37 (+9)
29% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 7
0.3% more ownership
Funds ownership: 0.42% → 0.72% (+0.3%)
34% less capital invested
Capital invested by funds: $6.78M → $4.45M (-$2.33M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FPB
First PREMIER Bank
Sioux Falls,
South Dakota
|
+$1.37M |
| 2 |
MC
Meteora Capital
Boca Raton,
Florida
|
+$614K |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$176K |
| 4 |
Millennium Management
New York
|
+$135K |
| 5 |
BlackRock
New York
|
+$115K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AA
ALPS Advisors
Denver,
Colorado
|
-$170K |
| 2 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$91K |
| 3 |
Citigroup
New York
|
-$13.4K |
| 4 |
JP Morgan Chase
New York
|
-$6.7K |
| 5 |
WAM
Wolverine Asset Management
Chicago,
Illinois
|
-$5.25K |
SABS Hedge Fund Activity: Q2 2022 in Review
37 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in SAB Biotherapeutics (SABS) for Q2 2022, worth a combined $4.45M — down 34% from $6.78M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new SABS positions and 3 closed out — a net gain of 9 holders — while 9 added to existing stakes and 7 trimmed.
The largest buyer was First PREMIER Bank, opening a new position worth an estimated $1.37M. The largest seller was ALPS Advisors, exiting entirely with an estimated $170K sold.
- 37 institutional investors held SAB Biotherapeutics (SABS) as of Q2 2022, up from 28 in Q1 2022.
- Funds reported $4.45M of SAB Biotherapeutics stock for Q2 2022, down 34% quarter-over-quarter.
- 12 funds opened new SAB Biotherapeutics positions in Q2 2022 and 3 closed out, a net change of +9 holders.
- The largest SAB Biotherapeutics buyer in Q2 2022 was First PREMIER Bank, an estimated $1.37M added.
- The largest SAB Biotherapeutics seller in Q2 2022 was ALPS Advisors, an estimated $170K sold.
Based on aggregated 13F filings for Q2 2022.